Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060203 · ClinicalTrials.gov registry record · Phase 1
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00060203 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT00060203, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who have recurrent or refractory multiple myeloma.
Interventions
- DRUG brostallicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2002-12 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060203
The ClinicalTrials.gov registry entry for NCT00060203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brostallicin is the first listed.
NCT00060203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060203 about?
NCT00060203 is a clinical study titled "Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who have recurrent or refractory multiple myeloma.
What is the current status of trial NCT00060203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2002-12. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00060203?
The interventions under investigation include: brostallicin (DRUG).
Who is sponsoring clinical trial NCT00060203?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.